Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer's 3Q Revenues up 31% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Pfizer’s 3Q Revenues up 31%

Legacy Seagen sales, Vyndaqel, Eliquis, and Xtandi drive growth.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer 
3Q Revenues: $17.7 billion (+31%)
3Q Earnings: $4.5 billion (loss of $2.4 billion 3Q23)  
YTD Revenues: $45.9 billion (+2%)
YTD Earnings: $7.6 billion (+39%)
Comments: Growth in the quarter was driven by revenues of $854 million from legacy Seagen, which was acquired in December of 2023; Vyndaqel family sales, up 63% operationally; Eliquis, up 9% operationally, Xtandi, up 28% operationally; and Nurtec ODT/Vydura globally, up 45% operationally. Growth was partially offset by lower revenues for: Xeljanz, down 35% operationally; and Ibrance, down 12% operationally. Paxlovid revenue was $2.7 billion, compared to $202 million in 3Q23. Comirnaty revenues were $1.4 billion, up 9%. Pfizer CentreOne revenues were $285 million in the quarter, down 3%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters